 |
 |
|
Urigen's pipeline includes URG101, targeting the treatment of painful bladder syndrome (PBS), symptoms of pelvic bladder syndrome secondary to pelvic irradiation and dyspareunia; URG301, targeting acute urgency in patients diagnosed with overactive bladder, acute urethral discomfort and urethritis; and URG302, a follow-on program targeting acute urgency in patients diagnosed with overactive bladder.
|
 View the product pipeline |
|
|
 |
 |
|
Jan 13, 2010, San Francisco, California - Prof. Lowell Parsons Presents Urigen at One Med Place Conference. Click here to view the slides
Oct 30, 2009, San Francisco, California - Urigen Overview of IC/Painful Bladder Syndrome for IC Awareness Week Click here. Click here to view the slides
May 29-Jun 3, 2010, San Francisco, California - Urigen will be attending the American Urological Association (AUA) 2010 Annual Meeting Click here.
|
|
|
 |
 |
|
Aug 18, 2010 - FDA Grants Urigen's URG101 Meeting
Aug 11, 2010 - Urigen Pharmaceuticals Announces FDA Follow Up
Jul 6, 2010 - Urigen FDA and Management Update
Apr 26, 2010 - Urigen Restructures Debt as Preferred Stock
Apr 23, 2010 - Urigen Files Request for FDA Meeting
Mar 18, 2010 - Urigen CEO Interview on Urigen.com
Mar 3, 2010 - Edward R. Teitel, MD, JD Becomes Chairman of Urigen
Jan 12 2009 - Urigen Pharmaceuticals Completes $257,000 Financing
Aug 19 2008 - Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
Apr 25 2008 - Urigen Announces US Patent Office Notice of Allowance of Claims for URG101
Mar 12 2008 - Urigen Announces Positive Phase II Clinical Trial Results with URG101
|
| Archives |
|
|
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications.
Urigen has two primary programs in development that are either in or positioned to enter Phase II clinical trials.
|
 |
|
